Stocks fell sharply on Thursday as U.S.-China trade worries persisted with more companies suspending business with Chinese telecom giant Huawei.Marketsread more
The yield on the 10-year Treasury note fell to its lowest level since 2017 as more traders grew confident in a longer U.S.-China conflict.Bondsread more
A Ministry of Commerce spokesperson does not single out any U.S. action, but it's been a tense couple of weeks for the trade war.World Politicsread more
In a four-page letter sent Thursday morning, Warren and Ocasio-Cortez asked Mnuchin a series of questions about his advisory role in former Sears CEO Eddie Lampert's...Politicsread more
"For them to say that they don't work with the Chinese government is false," Secretary of State Mike Pompeo tells CNBC.Politicsread more
Facebook has stopped paying commission to staff for selling political advertisements on its platform, The Wall Street Journal reported.Technologyread more
Prosecutors allege that Stephen Calk, former president of Chicago-based Federal Savings Bank, loaned former Trump campaign chair Paul Manafort as much as $16 million in...Politicsread more
Oil prices tumble as the market braces for a prolonged U.S.-China trade war and on signs the U.S. is willing to negotiate with Iran.Energy Commoditiesread more
U.S. manufacturer growth hit new lows in May, the latest sign that the economic slowdown accelerated amid the ongoing trade war.Economyread more
European pilots are urging the EU's aviation regulator to conduct an independent and thorough review of the Boeing 737 Max before it flies again. The planes have been grounded...Airlinesread more
Wall Street is under pressure, but a handful of stocks are breaking out to new highs. McDonald's, Waste Management, Hershey, Visa and Costco have notched records this month,...Trading Nationread more
The Food and Drug Administration said Tuesday it has sent a warning letter to drug distributor McKessson for allegedly shipping "illegitimate" opioid products and failing to properly handle and investigate the incidents.
Specifically, the FDA is accusing McKesson of failing to identify, quarantine and investigate drug shipments that had been tampered with. Some of the bad shipments were discovered at three Rite Aid pharmacies in Michigan. This is the first time the FDA has issued a warning letter under the 2013 Drug Supply Chain Security Act.
Distributors have come under fire for their role in the opioid crisis. McKesson and Cardinal Health are the subject of numerous lawsuits alleging they flooded communities with opioids.
"A distributor's failure to have systems in place to investigate and quarantine suspect and illegitimate products within their control is a violation of the law. But this is even more concerning given that we're in the midst of a widespread opioid crisis," FDA Commissioner Scott Gottlieb said in a statement.
The warning letter was dated Feb. 7.
McKesson in a statement said it takes this situation "very seriously."
"We have been in communication with the FDA over the past several months to respond to their questions and we are in the process of providing additional procedural detail and documentation, including enhancements recently made in response to the FDA's initial feedback," the company said in a statement Tuesday. "We are committed to the security of the supply chain and are taking steps to help ensure we comply fully with FDA's track-and-trace laws for all pharmaceutical products."
In its warning letter, the FDA cited three examples where McKesson shipped prescription drugs that were supposed to be opioids and pharmacies discovered the opioid pills were removed and replaced with other products.
"This is simply unacceptable," Gottlieb said.
In September and October 2016, three Rite Aid pharmacies in Michigan reported receiving bottles oxycodone hydrochloride that were instead filled with naproxen and in one case, a combination of naproxen and ciprofloxacin hydrochloride, the FDA said.
Though McKesson investigated the incidents, the FDA said the company did not demonstrate that it identified all illegitimate products and notified its other customers who might have received products from the same batch.
In December 2016, Albertsons pharmacy submitted illegitimate product notifications for divalproex and losartan potassium and hydrochlorothiazide it received from McKesson because the packages allegedly did not contain lot numbers or expiration dates, the agency said.
The FDA also said in June 2016, drugmaker GlaxoSmithKline notified McKesson that a pharmacy reported receiving two sealed bottles of a product labeled as Triumeq that actually contained gemfibrozil. In this case, McKesson was unable to provide records showing it identified illegitimate product or other requirements, the FDA said.
Warning letters serve as the first step in any regulatory action the FDA may take against a company. The FDA floated taking possible legal action, including seeking an injunction.
McKesson has 15 days from the time it receives the letter to outline the steps it has taken to correct the violations flagged by the FDA and to identify and conduct investigations related to other reports of suspicious or illegitimate shipments.
Correction: This story was revised to correct that it's the first time the FDA has issued a warning letter under the 2013 Drug Supply Chain Security Act.